We are driven by the mission to improve the lives of people with cancer by transforming the efficacy of cancer surgery.
Our imaging, sensing and AI tools help surgeons to quickly and accurately detect cancer in real-time in the operating room, aiming to enhance surgical precision, improve patient outcomes, and reduce costs for healthcare systems.
Our Founder and Executive Chair, Dr David Tuch, introduces Lightpoint and our new miniature surgical probe for intra-operative cancer detection, SENSEI®.
Lightpoint signs commercial agreement with HOAM Medical for distribution of SENSEI®, our miniature gamma probe for minimally-invasive and robot-assisted surgery, in South Korea.
The brilliant team at UZ Leuven completed their first patient to help us evaluate SENSEI®, our miniature gamma probe for minimally-invasive and robot assisted surgery, in the treatment of prostate cancer.
Lightpoint and Telix agree strategic collaboration to explore how Lightpoint's innovative surgical devices and Telix's molecularly-targeted imaging agents can be used together for real-time intra-operative cancer detection.
Lightpoint has appointed Graeme Smith as CEO to focus on the commercialization of the company's recently approved miniaturized surgical probe, SENSEI®.
Lightpoint has secured market clearance in the US, EU, UK and Australia for SENSEI®, the company's new miniature gamma probe for minimally-invasive and robot-assisted cancer surgery,